10-Q
Quarterly Report
60 DEGREES PHARMACEUTICALS, INC.
SXTPW
NASDAQ
CIK: 1946563
File #: 001-41719
Balance Sheet
45 line items · 2 periods
XBRL
| Item | Sep 30, 2025 | Dec 31, 2024 |
|---|---|---|
ASSETS: | ||
Current Assets: | ||
Cash and Cash Equivalents | 4,115,779 | 1,659,353 |
Accounts Receivable | 674,036 | 486,748 |
Prepaid and Other Assets | 992,390 | 1,068,940 |
Short-Term Investments | 0 | 1,728,472 |
Inventory (Note 3) | 527,004 | 442,764 |
Total Current Assets | 6,309,209 | 5,386,277 |
Property and Equipment, net (Note 4) | 227,752 | 149,808 |
Other Assets: | ||
Long-Term Prepaid Expense | 0 | 66,176 |
Intangible Assets, net (Note 5) | 152,383 | 157,084 |
Total Other Assets | 152,383 | 223,260 |
Total Assets | 6,689,344 | 5,759,345 |
LIABILITIES AND SHAREHOLDERS' EQUITY: | ||
Current Liabilities: | ||
Accounts Payable and Accrued Expenses | 1,391,347 | 1,007,618 |
SBA EIDL (including accrued interest) (Note 7) | 8,772 | 8,772 |
Derivative Liabilities (Note 8) | 797,275 | 640,830 |
Contingent Milestone Payment - Fair Value, Inputs, Level 3 - Fair Value, Recurring | 797,275 | 640,830 |
Fair Value, Inputs, Level 3 | 797,275 | 640,830 |
Derivative Liabilities | 797,275 | 640,830 |
Fair Value, Inputs, Level 3 - Derivative Liabilities | 797,275 | 640,830 |
Total Current Liabilities | 2,197,394 | 1,657,220 |
Long-Term Liabilities: | ||
SBA EIDL (including accrued interest) (Note 7) | 144,992 | 147,119 |
Total Long-Term Liabilities | 144,992 | 147,119 |
Total Liabilities | 2,342,386 | 1,804,339 |
SHAREHOLDERS' EQUITY: | ||
Series A Preferred Stock, $0.0001 par value, 1,000,000 shares authorized; 76,480 and 76,480 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively (Note 6) | 9,567,439 | 9,567,439 |
Common Stock, $0.0001 par value, 150,000,000 shares authorized; 4,104,469 and 566,908 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively (Note 6) | 410 | 57 |
Additional Paid-in Capital(1) | 41,172,888 | 34,860,590 |
Accumulated Other Comprehensive Income | 144,039 | 135,471 |
Accumulated Deficit | (46,454,556) | (40,527,957) |
60P Shareholders’ Equity: | 4,430,220 | 4,035,600 |
Noncontrolling Interest | (83,262) | (80,594) |
Total Shareholders' Equity | 4,346,958 | 3,955,006 |
Common Stock, par value $0.0001 per share | 410 | 57 |
Series A - Preferred Stock | 9,567,439 | 9,567,439 |
Additional Paid-In Capital | 41,172,888 | 34,860,590 |
Accumulated Deficit | (46,454,556) | (40,527,957) |
Accumulated Other Comprehensive Income (Loss) | 144,039 | 135,471 |
Total Shareholders’ Equity (Deficit) Attributable to 60P | 4,430,220 | 4,035,600 |
Noncontrolling Interest on Shareholders | (83,262) | (80,594) |
Total Liabilities and Shareholders' Equity | 6,689,344 | 5,759,345 |